ClinicalTrials.gg
DrugBiological

Sotatercept clinical trials

Also written ACE-011, MK-7962 and WINREVAIR®.

studies test it
38
open now
11
in phase 3
6
first study started
2008

How each study uses sotatercept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the sotatercept studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
26 Mar 2024 · WINREVAIR · BLA 761363 (FDA, Drugs@FDA)
European Union
22 Aug 2024 · Winrevair · EMEA/H/C/005647 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sotatercept
33
ActRIIA-IgG1Fc
5
Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
2

Brand

WINREVAIR®
4

Development codes

ACE-011
28
MK-7962
13

Studies by the year they started

38 studies that test it; most in 2026 (7)

Studies that test sotatercept, by start year
YearStudies
20081
20091
20102
20111
20124
20132
20141
20181
20191
20214
20221
20234
20242
20256
20267

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
21
Phase 3
6
Phase 4
8

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 26 · Other 12

Merck Sharp & Dohme LLC (16) · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (6) · Celgene (4) · Philipps University Marburg (2) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · M.D. Anderson Cancer Center (1)

Often tested with

Tested in the same studies.

Selexipag (1) · Riociguat (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test sotatercept.

Studies

Open first, then newest update. How each study uses sotatercept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 38

See all 38 studies that test sotatercept →

Codes

What other systems call sotatercept · ClinicalTrials.gg INT005461

  • MeSH (NLM) C542017sotaterceptConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 0QI90BTJ37SOTATERCEPTConfirmed FDA, NLM, Wikidata
  • Wikidata Q103815273sotaterceptConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C80038SotaterceptOne source FDA
  • DrugBank DB12118One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.